JARVISDHL Screening Tools

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-99
SponsorNational Heart Centre Singapore

About this trial

The main purpose of this study is to pioneer an easy risk stratification tools, which is developed using novel artificial intelligence (AI) algorithms, that will be able to detect common and fatal heart diseases easily simply through a picture of the back of the eye, the retina. The retinal images will be analysed using a computer application with the risk stratification tool to predict health outcome of individual. The study also aims to correlate between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and clinical outcomes.

Eligibility criteria

Qualifiers

21 years of age or older

Sufficient language skills in English or Chinese

Provided informed consent

Completed CTCA or CT CAC in the past 6 months.

Disqualifiers

Patients whose informed consent was not obtained.

Age <21 years old

Patients with cardiac event (acute myocardial infarction, Stroke, heart failure, angina requiring hospitalization) and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) prior to CTCA

Patient whose informed consent was not obtained.

Trial design

Treatments tested in this trial

  • Ocular Imaging
  • Questionnaires

Treatment groups

2,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

National Heart Centre Singapore

Lead sponsor

Singapore Eye Research Institute

Collaborator